Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Sell
35
WST Quote, Financials, Valuation and Earnings
Last price:
$221.80
Seasonality move
:
3%
Day range:
$221.70 - $226.25
52-week range:
$187.43 - $352.33
Dividend yield:
0.37%
P/E ratio:
34.84x
P/S ratio:
5.62x
P/B ratio:
5.94x
Volume:
447.5K
Avg. volume:
612.5K
1-year change:
-34.01%
Market cap:
$15.9B
Revenue:
$2.9B
EPS (TTM):
$6.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$759.9M | $1.61 | 3.28% | -0.47% | $281.92 |
|
BSX
Boston Scientific
|
$4.9B | $0.70 | 18.78% | 229.3% | $117.02 |
|
PDEX
Pro-Dex
|
$15.3M | $0.50 | 19.14% | 4.44% | $56.00 |
|
PODD
Insulet
|
$644.7M | $1.10 | 25.31% | -64.13% | $334.74 |
|
TMCI
Treace Medical Concepts
|
$49.9M | -$0.24 | 5.9% | -21.86% | $9.73 |
|
UFPT
UFP Technologies
|
$152.4M | $2.33 | 37.56% | 28.57% | $311.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$221.91 | $281.92 | $15.9B | 34.84x | $0.21 | 0.37% | 5.62x |
|
BSX
Boston Scientific
|
$99.74 | $117.02 | $147.6B | 72.80x | $0.00 | 0% | 8.46x |
|
PDEX
Pro-Dex
|
$39.56 | $56.00 | $129M | 14.18x | $0.00 | 0% | 2.07x |
|
PODD
Insulet
|
$304.63 | $334.74 | $21.4B | 54.79x | $0.00 | 0% | 10.25x |
|
TMCI
Treace Medical Concepts
|
$5.67 | $9.73 | $356.7M | -- | $0.00 | 0% | 1.68x |
|
UFPT
UFP Technologies
|
$233.00 | $311.00 | $1.8B | 28.52x | $0.00 | 0% | 3.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
7.02% | 1.022 | 1.26% | 1.80x |
|
BSX
Boston Scientific
|
33.49% | 0.843 | 7.48% | 0.68x |
|
PDEX
Pro-Dex
|
34.14% | -1.397 | 11.31% | 1.41x |
|
PODD
Insulet
|
56.03% | 2.516 | 9.18% | 3.24x |
|
TMCI
Treace Medical Concepts
|
33.65% | 4.109 | 10.12% | 3.23x |
|
UFPT
UFP Technologies
|
33.63% | 3.172 | 11.76% | 1.39x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$231.9M | $127.6M | 16.23% | 17.47% | 15.89% | $58.1M |
|
BSX
Boston Scientific
|
$3.2B | $937M | 6.35% | 9.57% | 19.02% | $277M |
|
PDEX
Pro-Dex
|
$5.8M | $3.6M | 20.23% | 29.31% | 27.56% | $574K |
|
PODD
Insulet
|
$409M | $88.8M | 15.79% | 36.9% | 10.07% | $48.1M |
|
TMCI
Treace Medical Concepts
|
$41.9M | -$15.6M | -32% | -47.17% | -27.79% | $655K |
|
UFPT
UFP Technologies
|
$42.2M | $23.4M | 13.85% | 19.38% | 15.59% | $11M |
West Pharmaceutical Services vs. Competitors
-
Which has Higher Returns WST or BSX?
Boston Scientific has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 14.45%. West Pharmaceutical Services's return on equity of 17.47% beat Boston Scientific's return on equity of 9.57%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B BSXBoston Scientific68.84% $0.45 $33.6B -
What do Analysts Say About WST or BSX?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 27.04%. On the other hand Boston Scientific has an analysts' consensus of $117.02 which suggests that it could grow by 17.33%. Given that West Pharmaceutical Services has higher upside potential than Boston Scientific, analysts believe West Pharmaceutical Services is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 1 0 BSXBoston Scientific23 3 0 -
Is WST or BSX More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.681, suggesting its less volatile than the S&P 500 by 31.908%.
-
Which is a Better Dividend Stock WST or BSX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BSX?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Boston Scientific quarterly revenues of $4.7B. West Pharmaceutical Services's net income of $89.8M is lower than Boston Scientific's net income of $674M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.84x while Boston Scientific's PE ratio is 72.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.62x versus 8.46x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.62x 34.84x $698M $89.8M BSXBoston Scientific8.46x 72.80x $4.7B $674M
-
Which has Higher Returns WST or PDEX?
Pro-Dex has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 18.81%. West Pharmaceutical Services's return on equity of 17.47% beat Pro-Dex's return on equity of 29.31%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B PDEXPro-Dex33.3% $0.98 $53.6M -
What do Analysts Say About WST or PDEX?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 27.04%. On the other hand Pro-Dex has an analysts' consensus of $56.00 which suggests that it could grow by 41.56%. Given that Pro-Dex has higher upside potential than West Pharmaceutical Services, analysts believe Pro-Dex is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 1 0 PDEXPro-Dex1 0 0 -
Is WST or PDEX More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.086%.
-
Which is a Better Dividend Stock WST or PDEX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or PDEX?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Pro-Dex quarterly revenues of $17.4M. West Pharmaceutical Services's net income of $89.8M is higher than Pro-Dex's net income of $3.3M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.84x while Pro-Dex's PE ratio is 14.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.62x versus 2.07x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.62x 34.84x $698M $89.8M PDEXPro-Dex2.07x 14.18x $17.4M $3.3M
-
Which has Higher Returns WST or PODD?
Insulet has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 6.22%. West Pharmaceutical Services's return on equity of 17.47% beat Insulet's return on equity of 36.9%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B PODDInsulet71.88% $0.50 $3B -
What do Analysts Say About WST or PODD?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 27.04%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.89%. Given that West Pharmaceutical Services has higher upside potential than Insulet, analysts believe West Pharmaceutical Services is more attractive than Insulet.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 1 0 PODDInsulet14 2 0 -
Is WST or PODD More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.
-
Which is a Better Dividend Stock WST or PODD?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or PODD?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Insulet quarterly revenues of $569M. West Pharmaceutical Services's net income of $89.8M is higher than Insulet's net income of $35.4M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.84x while Insulet's PE ratio is 54.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.62x versus 10.25x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.62x 34.84x $698M $89.8M PODDInsulet10.25x 54.79x $569M $35.4M
-
Which has Higher Returns WST or TMCI?
Treace Medical Concepts has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of -30.29%. West Pharmaceutical Services's return on equity of 17.47% beat Treace Medical Concepts's return on equity of -47.17%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B TMCITreace Medical Concepts79.69% -$0.25 $158.8M -
What do Analysts Say About WST or TMCI?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 27.04%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 71.58%. Given that Treace Medical Concepts has higher upside potential than West Pharmaceutical Services, analysts believe Treace Medical Concepts is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 1 0 TMCITreace Medical Concepts2 5 0 -
Is WST or TMCI More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WST or TMCI?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or TMCI?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. West Pharmaceutical Services's net income of $89.8M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.84x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.62x versus 1.68x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.62x 34.84x $698M $89.8M TMCITreace Medical Concepts1.68x -- $52.6M -$15.9M
-
Which has Higher Returns WST or UFPT?
UFP Technologies has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 11.6%. West Pharmaceutical Services's return on equity of 17.47% beat UFP Technologies's return on equity of 19.38%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B UFPTUFP Technologies28.45% $2.21 $543.4M -
What do Analysts Say About WST or UFPT?
West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 27.04%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 33.48%. Given that UFP Technologies has higher upside potential than West Pharmaceutical Services, analysts believe UFP Technologies is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 1 0 UFPTUFP Technologies1 2 0 -
Is WST or UFPT More Risky?
West Pharmaceutical Services has a beta of 1.092, which suggesting that the stock is 9.216% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.118, suggesting its more volatile than the S&P 500 by 11.848%.
-
Which is a Better Dividend Stock WST or UFPT?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or UFPT?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than UFP Technologies quarterly revenues of $148.1M. West Pharmaceutical Services's net income of $89.8M is higher than UFP Technologies's net income of $17.2M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.84x while UFP Technologies's PE ratio is 28.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.62x versus 3.31x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.62x 34.84x $698M $89.8M UFPTUFP Technologies3.31x 28.52x $148.1M $17.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
